SCHEMBL4522091

SCHEMBL4522091

Cc1c(C(=O)c2ccc(N)c(C(=O)O)c2)c2ccccn2c1NC(=O)c1cccc(OCCNS(=O)(=O)c2cccc(S(=O)(=O)NCCOc3cccc(C(=O)Nc4c(C)c(C(=O)c5ccc(N)c(C(=O)O)c5)c5ccccn45)c3)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 4/20 0.38
KAT6A Q92794 4/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
MEN1 O00255 1/20 0.34
NR1H4 Q96RI1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1573016 0.88 ALDH1A1 (0.40) RAB9AALDH1A1SMN1; SMN2MAPK1KMT2A
SCHEMBL1573173 0.88 NR1H4 (0.42) ALDH1A1KMT2AMAPTAKR1C2AKR1C1
SCHEMBL4522090 0.88 LMNA (0.39) RAB9AALDH1A1KAT6ALMNASMN1; SMN2
SCHEMBL4518703 0.87 KMT2A (0.41) ALDH1A1KMT2AMAPTAKR1C2AKR1C1
SCHEMBL1572823 0.87 ALDH1A1 (0.39) RAB9AALDH1A1SMN1; SMN2MAPK1KMT2A
SCHEMBL1573410 0.84 ALDH1A1 (0.42) RAB9AALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL4496429 0.83 KMT2A (0.44) RAB9AALDH1A1SMN1; SMN2MAPK1KMT2A
SCHEMBL1572786 0.83 ALDH1A1 (0.41) RAB9AALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL1573141 0.83 ALDH1A1 (0.41) RAB9AALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL4506386 0.81 KMT2A (0.43) RAB9AALDH1A1SMN1; SMN2MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 RAB9A 1820/4885ALDH1A1 1044/4885KAT6A 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.